Spruce Biosciences (NASDAQ:SPRB – Get Rating) and Cocrystal Pharma (NASDAQ:COCP – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Analyst Ratings
This is a summary of current ratings for Spruce Biosciences and Cocrystal Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spruce Biosciences | 0 | 0 | 5 | 0 | 3.00 |
| Cocrystal Pharma | 0 | 0 | 2 | 0 | 3.00 |
Spruce Biosciences currently has a consensus price target of $7.60, indicating a potential upside of 243.89%. Given Spruce Biosciences’ higher possible upside, equities analysts plainly believe Spruce Biosciences is more favorable than Cocrystal Pharma.
Volatility and Risk
Profitability
This table compares Spruce Biosciences and Cocrystal Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spruce Biosciences | N/A | -54.92% | -46.13% |
| Cocrystal Pharma | N/A | -35.16% | -33.88% |
Institutional & Insider Ownership
84.2% of Spruce Biosciences shares are owned by institutional investors. 5.9% of Spruce Biosciences shares are owned by company insiders. Comparatively, 5.5% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Spruce Biosciences and Cocrystal Pharma’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spruce Biosciences | N/A | N/A | -$46.18 million | ($1.96) | -1.13 |
| Cocrystal Pharma | $2.01 million | 7.82 | -$38.84 million | ($4.73) | -0.41 |
Cocrystal Pharma has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Spruce Biosciences beats Cocrystal Pharma on 6 of the 11 factors compared between the two stocks.
About Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
About Cocrystal Pharma
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
